This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
JACC Specialty Journals
JACC Asia - Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
Released: Aug 15, 2023
Commentary by Dr Jian-Jun Li
JACC Asia - Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
00:00:00
